The global insomnia treatment market size was estimated to be USD 3.68 billion in 2023 and is expected to reach at USD 6.94 billion by 2034 with a CAGR of 5.93% during the forecast period 2024-2034. Rise in prevalence of insomnia, increasing stress levels, growing awareness regarding various treatment options for insomnia, surge in technological advancements, rising launch of novel products, increasing research & development activities, growing mental depression disorders, and surge in innovative product developments for the treatment of insomnia are some of the key factors boosting the market growth.
Surge in innovative product developments for the treatment of insomnia is predicted to boost the market growth during the forecast period. Insomnia, a prevalent sleep disorder, can lead to difficulties in initiating sleep, maintaining sleep, or early awakening with an inability to return to sleep. Consequently, industry participants are prioritizing the creation of innovative devices in this regard. For instance, in June 2022, Pear Therapeutics has presented interim follow-up real-world data from a decentralized trial indicating that the use of Somryst, an FDA-approved digital therapeutic for chronic insomnia, resulted in a significant reduction in the severity of insomnia, anxiety, and depression symptoms.
By treatment, drug was the highest revenue-grossing segment in the global insomnia treatment market in 2023 owing to the benefits associated with the orexin class of drugs, growing product approvals by regulatory bodies, surge in prevalence of insomnia or difficulty falling asleep, and increasing research & development activities. For instance, in October 2022, Idorsia Pharmaceuticals Japan has reported favorable top-line findings from a Phase 3 clinical trial conducted in Japan. This study assessed the effects of Idorsia's dual orexin receptor antagonist, daridorexant, in doses of 25 mg and 50 mg in 490 randomized patients, including both adults and elderly individuals (30.1% aged 65 years or older) diagnosed with insomnia disorder. Additionally, devices is predicted to grow at fastest CAGR during the forecast period owing to the rising technological advancements and growing focus on manufacturing of cutting-edge devices.
By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global insomnia treatment market in 2023 owing to the majority of those with sleep problems utilize prescription medications and seek professional assistance, surge in use of prescription pharmaceuticals, and increasing approvals by regulatory bodies. For instance, in May 2022, The European Commission has granted marketing authorization to Idorsia Ltd for QUVIVIQ, a medication designed for the treatment of insomnia in adult patients. This insomnia should be characterized by symptoms persisting for a minimum of three months and having a significant impact on daytime functioning. Additionally, retail pharmacies is predicted to grow at fastest CAGR during the forecast period owing to the increasing number of retail pharmacies, and growing approvals by regulatory bodies.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in need for sleep disorder treatment, growing prevalence of sleep disorders, increasing government support in the form of funding for insomnia treatment, rising research & development of new drugs, and surge in product approvals by regulatory bodies. For instance, in January 2023, The FDA has granted Zydus Lifesciences Ltd the ultimate approval to market its generic Triazolam pills, which are used to treat short-term insomnia. According to a regulatory disclosure by the manufacturer, US authorities have authorized the company to distribute Triazolam pills in 0.125 mg and 0.25 mg strengths. This medication is prescribed for individuals with short-term insomnia, and it induces sleep by reducing brain activity. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of sleep disorders, presence of major market players, and rising product launches. For instance, in April 2023, Bukwang Pharmaceutical has announced the launch of Zaledeep Cap., a medication designed to address insomnia and featuring zaleplon as its primary ingredient. Bukwang anticipates that the introduction of Zaledeep Cap., the first of its kind in Korea to utilize zaleplon, will provide a new treatment option for individuals dealing with insomnia. Research has demonstrated that Zaleplon offers swift onset of action, effectively induces sleep in insomnia patients, has a short half-life, causes minimal disruption to daily activities, and leads to minimal rebound insomnia. The FDA has already granted marketing approval for zaleplon, a non-benzodiazepine medication, for insomnia treatment.
Surge in innovative product developments for the treatment of insomnia is predicted to boost the market growth during the forecast period. Insomnia, a prevalent sleep disorder, can lead to difficulties in initiating sleep, maintaining sleep, or early awakening with an inability to return to sleep. Consequently, industry participants are prioritizing the creation of innovative devices in this regard. For instance, in June 2022, Pear Therapeutics has presented interim follow-up real-world data from a decentralized trial indicating that the use of Somryst, an FDA-approved digital therapeutic for chronic insomnia, resulted in a significant reduction in the severity of insomnia, anxiety, and depression symptoms.
By treatment, drug was the highest revenue-grossing segment in the global insomnia treatment market in 2023 owing to the benefits associated with the orexin class of drugs, growing product approvals by regulatory bodies, surge in prevalence of insomnia or difficulty falling asleep, and increasing research & development activities. For instance, in October 2022, Idorsia Pharmaceuticals Japan has reported favorable top-line findings from a Phase 3 clinical trial conducted in Japan. This study assessed the effects of Idorsia's dual orexin receptor antagonist, daridorexant, in doses of 25 mg and 50 mg in 490 randomized patients, including both adults and elderly individuals (30.1% aged 65 years or older) diagnosed with insomnia disorder. Additionally, devices is predicted to grow at fastest CAGR during the forecast period owing to the rising technological advancements and growing focus on manufacturing of cutting-edge devices.
By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global insomnia treatment market in 2023 owing to the majority of those with sleep problems utilize prescription medications and seek professional assistance, surge in use of prescription pharmaceuticals, and increasing approvals by regulatory bodies. For instance, in May 2022, The European Commission has granted marketing authorization to Idorsia Ltd for QUVIVIQ, a medication designed for the treatment of insomnia in adult patients. This insomnia should be characterized by symptoms persisting for a minimum of three months and having a significant impact on daytime functioning. Additionally, retail pharmacies is predicted to grow at fastest CAGR during the forecast period owing to the increasing number of retail pharmacies, and growing approvals by regulatory bodies.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in need for sleep disorder treatment, growing prevalence of sleep disorders, increasing government support in the form of funding for insomnia treatment, rising research & development of new drugs, and surge in product approvals by regulatory bodies. For instance, in January 2023, The FDA has granted Zydus Lifesciences Ltd the ultimate approval to market its generic Triazolam pills, which are used to treat short-term insomnia. According to a regulatory disclosure by the manufacturer, US authorities have authorized the company to distribute Triazolam pills in 0.125 mg and 0.25 mg strengths. This medication is prescribed for individuals with short-term insomnia, and it induces sleep by reducing brain activity. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of sleep disorders, presence of major market players, and rising product launches. For instance, in April 2023, Bukwang Pharmaceutical has announced the launch of Zaledeep Cap., a medication designed to address insomnia and featuring zaleplon as its primary ingredient. Bukwang anticipates that the introduction of Zaledeep Cap., the first of its kind in Korea to utilize zaleplon, will provide a new treatment option for individuals dealing with insomnia. Research has demonstrated that Zaleplon offers swift onset of action, effectively induces sleep in insomnia patients, has a short half-life, causes minimal disruption to daily activities, and leads to minimal rebound insomnia. The FDA has already granted marketing approval for zaleplon, a non-benzodiazepine medication, for insomnia treatment.
Segmentation: Insomnia Treatment Market Report 2023 - 2034
Insomnia Treatment Market Analysis & Forecast by Treatment 2023 - 2034 (Revenue USD Bn)
- Devices
- Drug
- Benzodiazepines
- Antidepressants
- Nonbenzodiazepines
- Melatonin Antagonist
- Orexin Antagonist
- Others
Insomnia Treatment Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Retail Pharmacies
- Hospital Pharmacies
- Others
Insomnia Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Insomnia Treatment Market: Treatment Estimates & Trend Analysis
8. Insomnia Treatment Market: Distribution Channel Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Insomnia Treatment Market
11. Europe Global Insomnia Treatment Market
12. Asia Pacific Global Insomnia Treatment Market
13. Latin America Global Insomnia Treatment Market
14. MEA Global Insomnia Treatment Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Paratek Pharmaceuticals Inc.
- Merck & Co.
- Takeda Pharmaceutical Company Ltd
- Pfizer Inc.
- Meda Consumer Healthcare
- Sanofi SA
- Electromedical Products International Inc.
- Cerêve Inc.
- Purdue Pharma LP
- Innovative Neurological Devices
- Ebb Therapeutics
- Eisai Co. Ltd
- Pernix Therapeutics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 3.68 Billion |
| Forecasted Market Value ( USD | $ 6.94 Billion |
| Compound Annual Growth Rate | 5.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
